Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients

Inclusion Criteria: * For women of childbearing age, negative serum pregnancy test at screening. * Severe chronic kidney disease (TFGe lower than 30 ml/min) OR end-stage kidney disease on peritoneal dialysis. * Anaemia, as defined by haemoglobin (Hb) \< 120 g/L, within 14 days prior to screening, in a patient with or without an Erythropoiesis-stimulating agent (ESA). * Iron depletion, as defined by transferrin saturation (TSAT) \< 20% and/or a ferritin assay (FERR) \< 200, within 14 days prior to screening. * If an ESA is used, stable dose over the past 60 days. Exclusion Criteria: * Allergy to ferumoxytol or another intravenous iron formulation. * Administration of ferumoxytol or any other intravenous, intramuscular or oral iron formulation within 30 days of enrolment. * Patient who have received a blood transfusion within 2 weeks prior to enrolment, or are planned to receive a blood transfusion over the duration of the study. * Patient currently participating in a clinical trial with another investigational drug or device or who have received an investigational drug or device within 30 days of enrolment in this study. * Hb \< 90 g/L at the time of screening. * Existing or clinically suspected bleeding of digestive, gynaecological or other origin. * Patient who have another cause of anemia, other than iron deficiency (for example, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, myelodysplastic disorder, etc.). * Patients who are not responding to ESA or who are receiving in excess of 30000 units/week of erythropoietin (EPO), or 150 mcg/week of darbepoietin alfa. * Major surgery within one month prior to enrolment in the study or planned surgery, other than vascular access creation, while the patient is in on the study. * Patient who have had a malignancy (except for non-melanoma cancer of the skin) unless the patient has received curative treatment and has been disease-free for \> 2 years. * Patient who are considered by the Investigator to have a medical status that would preclude the patient's participation in this protocol. * Patient due to have a magnetic resonance imaging examination or in whom such an examination is planned, in the next three months. * Woman who plans to become pregnant in the next three months. * Woman that is breastfeeding. * Ongoing or recent (\< 2 weeks) bacterial infection requiring treatment. * Patient unable to give informed consent. * Patient refuses to give informed consent.